Total metabolic tumor volume on 18 F-FDG PET/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Purpose: Because of atypical response imaging patterns in patients with metastatic non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICPIs), new biomarkers are needed for a better monitoring of treatment efficacy. The aim of this prospective study was to evaluate the prognostic value of volume-derived positron-emission tomography (PET) parameters on baseline and follow-up 18 F-fluoro-deoxy-glucose PET ( 18 F-FDG-PET) scans and compare it with the conventional PET Response Criteria in Solid Tumors (PERCIST). Methods: Patients with metastatic NSCLC were included in two different single-center prospective trials. 18 F-FDG-PET studies were performed before the start of immunotherapy (PET baseline ), after 6–8 weeks (PET interim 1) and after 12–16 weeks (PET interim 2) of treatment, using PERCIST criteria for tumor response assessment. Different metabolic parameters were evaluated: absolute values of maximum standardized uptake value (SUVmax) of the most intense lesion, total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), but also their percentage changes between PET studies (ΔSUVmax, ΔTMTV and ΔTLG). The median follow-up of patients was 31 (7.3–31.8) months. Prognostic values and optimal thresholds of PET parameters were estimated by ROC (Receiver Operating Characteristic) curve analysis of 12-month overall survival (12M-OS) and 6-month progression-free survival (6M-PFS). Tumor progression needed to be confirmed by a multidisciplinary tumor board, considering atypical response patterns on imaging. Results: 110 patients were prospectively included. On PET baseline , TMTV was predictive of 12M-OS [AUC (Area Under Curve) =0.64; 95% CI: 0.61 to 0.66] whereas SUVmax and TLG were not. On PET interim 1 and PET interim 2, all metabolic parameters were predictive for 12M-OS and 6M-PFS, the residual TMTV on PET interim 1 (TMTV 1 ) being the strongest prognostic biomarker (AUC=0.83 and 0.82; 95% CI: 0.74 to 0.91, for 12M-OS and 6M-PFS, respectively). Using the optimal threshold by ROC curve to classify patients into three TMTV 1 subgroups (0 cm 3 ; 0–57 cm 3 ; >57 cm 3 ), TMTV 1 prognostic stratification was independent of PERCIST criteria on both PFS and OS, and significantly outperformed them. Subgroup analysis demonstrated that TMTV 1 remained a strong prognostic biomarker of 12M-OS for non-responding patients (p=0.0003) according to PERCIST criteria. In the specific group of patients with PERCIST progression on PET interim 1, low residual tumor volume (<57 cm 3 ) was still associated with a very favorable patients’ outcome (6M-PFS=73%; 24M-OS=55%). Conclusion: The absolute value of residual metabolic tumor volume, assessed 6–8 weeks after the start of ICPI, is an optimal and independent prognostic measure, exceeding and complementing conventional PERCIST criteria. Oncologists should consider it in patients with first tumor progression according to PERCIST criteria, as it helps identify patients who benefit from continued treatment. Trial registration number: 2018-A02116-49; NCT03584334 .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,664
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney, G. T., Weiner, L. M., & Atkins, M. B. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30406-5 · Cited by 1,635
Nioche, C., Orlhac, F., Boughdad, S., Reuzé, S., Goya-Outi, J., Robert, C., Pellot-Barakat, C., Soussan, M., Frouin, F., & Buvat, I. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0125 · Cited by 1,167
Davis, A. A., & Patel, V. G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0768-9 · Cited by 960
Research works printed but not linked: 6
- 20. Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143-52. · DOI · Paper page
- 23. Nabet BY, Esfahani MS, Moding EJ, et al. Noninvasive early identification of therapeutic benefit from immune Checkpoint inhibition. Cell 2020;183:363-76. · DOI · Paper page
- 27. Im H-J, Kim YK, Kim Y-I, et al. Usefulness of combined metabolic- volumetric indices of 18F-FDG PET/CT for the early prediction of neoadjuvant chemotherapy outcomes in breast cancer. Nucl Med Mol Imaging 2013;47:36-43. · DOI
- 29. Driessen J, Zwezerijnen GJC, Schöder H, et al. The impact of semiautomatic segmentation methods on metabolic tumor volume, intensity, and dissemination radiomics in 18 F -FDG PET scans of patients with classical Hodgkin lymphoma. J Nucl Med 2022;63:1424-30. · DOI
- 32. Capobianco N, Meignan M, Cottereau A-S, et al. Deep-learning 18F-FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma. J Nucl Med 2021;62:30-6. · DOI
- 36. 18 F]FDG PET/CT imaging and clinical features. Cancers (Basel) 2023;15:4083. on April 22, 2024 by guest. Protected by copyright. http://jitc.bmj.com/ J Immunother Cancer: first published as 10.1136/jitc-2023-007628 on 22 April 2024. Downloaded from
Cited by
Tumour and microenvironment crosstalk in NSCLC progression and response to therapy
Rahal, Z., Darzi, R. E., Moghaddam, S. J., Cascone, T., & Kadara, H. N. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01021-1 · Cited by 122
Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors
Huang, L., Li, Y., Zhang, C., Jiang, A., Zhu, L., Mou, W., Li, K., Zhang, J., Cui, C., Cui, X., et al. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00819-2 · Cited by 28
Zheng, J., Xu, S., Wang, G., & Shi, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1434171 · Cited by 28
Huang, M., Zou, Y., Wang, W., Li, Q., & Tian, R. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241293364 · Cited by 23
“20,21 The prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) is frequently reported in many cancers, 22–25 as well as in NSCLC patients undergoing surgery, chemotherapy, or radiotherapy.”
BackgroundMolecular PET imaging: Unlocking the secrets of cancer metabolism
Garg, P., Singhal, G., Horne, D. A., Kulkarni, P., Salgia, R., & Singhal, S. S. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117202 · Cited by 23
Cheng, Y., Jiang, Z.-P., Chen, X., Lu, K.-Y., Liu, Z., & Shao, D. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005863 · Cited by 16
The Role of [18F]FDG PET/CT in Monitoring of Therapy Response in Lung Cancer
Ayeni, O. A., Evbuomwan, O., & Vangu, M.-D.-T. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.02.002 · Cited by 15
Agarwal, A., Wehrle, C. J., Satish, S., Mahajan, P., Kamath, S. D., Koyfman, S. A., Ma, W. W., Linganna, M. W., Esfeh, J. M., Miller, C. A. S., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13010123 · Cited by 14
Qiao, T., Cheng, Z., & Duan, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1530507 · Cited by 11
Tao, X., Zhang, Q., Li, N., Wang, S., Guo, W., Yuan, P., Ying, J., Li, J., Guo, L., Tang, W., et al. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005910 · Cited by 9
Artificial Intelligence for Drug Discovery: An Update and Future Prospects
Howell, H. J., McGale, J., Choucair, A., Shirini, D., Aide, N., Postow, M. A., Wang, L., Tordjman, M., Lopci, E., Lecler, A., et al. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.01.004 · Cited by 9
Hreich, S. J. D., Humbert, O., Pacé-Loscos, T., Schiappa, R., Juhel, T., Ilié, M., Ferrari, V., Benzaquen, J., Hofman, P. M., & Vouret‐Craviari, V. (2024) · Cancers · doi:10.3390/cancers16122226 · Cited by 8
“In particular, we showed that 18 FDG PET enables early assessment of treatment-induced metabolic changes in the tumor or tissue inflammation linked to immune-related adverse events [13].”
BackgroundSelf-citationZhang, Y., Xu, M., Wang, Y., Yu, F. F., Chen, X., Wang, G., Zhao, K., Yang, H., & Su, X. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07084-7 · Cited by 6
CAR T-cell therapy induced pseudoprogression
Dean, E. A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1691562 · Cited by 5
“…a more reliable measurement compared to another potential prognostic radiologic marker, total lesion glycolysis (TLG), which is obtained by multiplying MTV by the mean standardized uptake value (SUV mean ) for each hypermetabolic lesion, since SUV mean depends on the imaging technique (23).”
InfluentialAuriac, J., Lemoudda, G., Hovhannisyan, N., Pires, M., Sundar, L. K. S., Feghali, P. S., Seban, R., Jehanno, N., Nioche, C., Luporsi, M., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271400 · Cited by 4
“…metabolic tumor volume (TMTV), total lesion glycolysis (TLG), SUV max , and the maximum distance between 2 lesions (D max ) are PET-derived biomarkers re fl ecting metabolic tumor burden, tumor activity, and disease dissemination and have a strong prognostic value for patient survival ( 5 – 7 ).”
Circulating Tumor DNA and [18F]FDG-PET for Early Response Assessment in Patients with Advanced NSCLC
Ryssel, H., Ahlborn, L. B., Dejanović, D., Keller, S. H., Poehl, M., Østrup, O., Loft, A., Fischer, B. M., Langer, S. W., Kjær, A., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15030247 · Cited by 4
Toward Integrated Clinical-Computational Nuclear Medicine
Farhadi, F., Esfahani, S. A., Yousefirizi, F., Luo, M., Fernandez, P. E., Sitek, A., Sabet, H., Saboury, B., Rahmim, A., & Heidari, P. (2025) · PET Clinics · doi:10.1016/j.cpet.2025.09.003 · Cited by 3
Weissensee, A., Bregenzer, C., Viscione, M., Mingels, C., Sari, H., Caobelli, F., Seifert, R., Rominger, A., & Pyka, T. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006278 · Cited by 3
Artificial Intelligence for Predicting Immunotherapy Efficacy in Non-Small Cell Lung Cancer
Cao, P., Jia, X., Yang, Y., Wang, X., Zhu, J., Li, X., Yang, Z., & Wen, Q. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s581764 · Cited by 3
Applications of artificial intelligence in nuclear medicine
Kaiser, L., Wendler, T., Hardiansyah, D., Hellwig, D., Lohmann, P., Nekolla, S. G., Papp, L., Ritt, P., Sundar, L. K. S., Tran‐Gia, J., et al. (2026) · Zeitschrift für Medizinische Physik · doi:10.1016/j.zemedi.2026.04.004 · Cited by 3
“In metastatic non-small cell lung cancer and melanoma receiving systemic therapy, higher metabolic tumor volume predicts inferior outcomes and is used to escalate or combine therapies in many centers [104,105].”
Cheng, Y., Huang, G.-J., Chen, X.-B., Zhu, H., Lu, K.-Y., Yang, F., Zhang, J., Liu, Z., & Shao, D. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108660 · Cited by 2
Advancing Positron Emission Tomography Image Quantification
Yousefirizi, F., Dassanayake, M., Lopez, A., Reader, A. J., Cook, G., Mingels, C., Rahmim, A., Seifert, R., & Alberts, I. (2025) · PET Clinics · doi:10.1016/j.cpet.2025.07.010 · Cited by 3
Christensen, T. N., Langer, S. W., Dejanović, D., Gillings, N., Madsen, J., Persson, G. F., Keller, S. H., Albrecht‐Beste, E., & Fischer, B. M. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270233 · Cited by 2
van der Hiel, B., der Veen, B. J. D. W., van den Eertwegh, A. J. M., Vogel, W. V., Stokkel, M. P. M., López‐Yurda, M., Boellaard, R., Kapiteijn, E., Hospers, G. A. P., Aarts, M. J. B., et al. (2025) · EJNMMI Research · doi:10.1186/s13550-025-01259-x · Cited by 2
Longitudinal assessment of lung lesion burden in CT
Mathai, T. S., Hou, B., & Summers, R. M. (2025) · SPIE Medical Imaging: Computer-Aided Diagnosis · doi:10.1117/12.3049018 · Cited by 3
“14 22 However, most prior approaches relied on proprietary datasets that are not publicly available or used commercially-developed algorithms.”
Quantitative Imaging Biomarkers in Lung Cancer: Current Trends and Future Directions
Prodigios, J., Kundalia, R., Acevedo, A., Bontemps, J., Pfaehler, D., Hasan, M. M. A., See, K. B., Verma, N., Hochhegger, D. R., Carvalho, A. R., et al. (2025) · Seminars in Roentgenology · doi:10.1053/j.ro.2025.06.002 · Cited by 1
Whi, W., Sun, J., Choi, J. O., & Lee, H. (2026) · BMC Medical Imaging · doi:10.1186/s12880-026-02475-0 · Cited by 1
“Unlike baseline pretherapeutic parameters, the percentage changes in volumetric parameters (Δ% MTV and Δ% TLG) were found to be associated with progression-free survival [22].”
Amrane, K., Cabarrou, B., Meur, C. L., Bourhis, D., Pradier, O., Misery, L., Legoupil, D., Étienne, M., Fontaine, G.-P., Salaün, P., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07727-9
“The change was statistically significant with prog - nostic value, as an increase or stability was associated with shown to be statistically significant and correlated with sur - vival in patients treated with ICB [41] and TKI [42].”
Nooreen, Z., Armo, R., Johri, H. V., Babu, R. H., Nehra, P., & Gasmi, A. (2026) · Current pharmacogenomics and personalized medicine (Online)/Current pharmacogenomics and personalized medicine · doi:10.2174/0118756921432491260401063552
Gupta, D. N., & Sood, S. (2026) · Research Square · doi:10.21203/rs.3.rs-9873079/v1
Thunold, S., Hernes, E., Mikalsen, L. T. G., Farooqi, S. J., Öjlert, Å. K., Francis, R. J., Nowak, A. K., Szejniuk, W. M., Nielsen, S. S., Cedrés, S., et al. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01469-x
Bülbül, O., Aydin, E., Nak, D., Bülbül, H. M., & Alyildiz, N. (2026) · Clinical and Translational Imaging · doi:10.1007/s40336-026-00784-6
Fan, M., Yao, Z., Guo, X., Hu, M., Zhang, F., Liu, G., Zhang, C., Zhao, J., & Chen, Y. (2026) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006588
Rotariu, L.-M., Alexa‐Stratulat, T., Tanasa, R., & Tanasa, M. P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1896427
“More recent PET-based studies indicate that metabolic tumor volume provides additional prognostic information beyond TNM staging and RECIST measurements, particularly in cohorts consisting exclusively of metastatic patients (54).”
Cheng, Y., Qin, T., Yang, F., Lu, K.-Y., Zhu, H., & Shao, D. (2026) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006675
Lee, E. S., Park, S. M., Lee, S., Kim, S., Choi, J., Lee, J. H., Eo, J. S., Kim, H. K., Yong, H. S., Chen, C. J., et al. (2026) · Translational Lung Cancer Research · doi:10.21037/tlcr-2026-0628
“Other groups have suggested that volumetric measures such as metabolic tumor volume (MTV) or total lesion glycolysis (TLG) provide additional prognostic value (13,14).”
Ma, M., Wang, W., Yang, G., & Shen, Z. (2026) · Applied Spectroscopy Reviews · doi:10.1080/05704928.2026.2720406
The Role of Artificial Intelligence in PET Imaging
Veziroglu, E. M., Dayma, K., Hasani, N., Kulkarni, R., Farhadi, F., & Klyuzhin, I. S. (2026) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2026.07.010
Lung Cancer and Thoracic Malignancies
Kiran, M. Y., & Özkan, Z. G. (2026) · Magnetic Resonance Imaging Clinics of North America · doi:10.1016/j.mric.2026.09.002
Wang, S., Yang, F., Lu, K.-Y., Zhu, H., Cheng, Y., & Shao, D. (2026) · Annals of Nuclear Medicine · doi:10.1007/s12149-026-02308-8
Metadata
- Authors
- Tricarico, P., Chardin, D., Martin, N., Contu, S., Hugonnet, F., Otto, J., & Humbert, O.
- Affiliations
- Centre Antoine Lacassagne (FR)
- Centre National de la Recherche Scientifique (FR)
- Princess Grace Hospital Centre (MC)
- Corresponding author
- Tricarico, Pierre
- Venue
- Journal for ImmunoTherapy of Cancer
- Publisher
- BMJ
- Published
- 2024-04
- Volume
- 12
- Issue
- 4
- Pages
- e007628
- ISSN
- 2051-1426 (ISSN-L)
- PMC
- PMC11043703
- OpenAlex
- W4395014773
- Semantic Scholar
- 9766d9be31cd4d12c52c055e1cef2684807ade6d
- Cited by
- 38
- References
- 37
- Citations by year
- 2026: 16 · 2025: 19 · 2024: 3
- FWCI
- 9.68
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-04-27)
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- 3IA cote d'azur (ANR-19-P3IA-0002)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Keywords
- total metabolic tumor volume, 18F-FDG PET/CT, metastatic non-small cell lung cancer, immune checkpoint inhibitors, immunotherapy response monitoring, prognostic factors, PERCIST criteria, SUVmax, total lesion glycolysis, overall survival, progression-free survival, treatment response prediction, treatment toxicity prediction, treatment de-escalation
- MeSH terms
- Positron Emission Tomography Computed Tomography, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Immunotherapy, Lung Neoplasms, Male, Middle Aged, Neoplasm Metastasis, Prospective Studies, Fluorodeoxyglucose F18, Tumor Burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.